Development of a Spirometry $T$-score in the General Population

Sei Won Lee  
*Ulsan University, South Korea*

Hyun Kuk Kim  
*Inje University, South Korea*

Seunghee Baek  
*Ulsan University, South Korea*

Ji-Ye Jung  
*Yonsei University, South Korea*

Young Sam Kim  
*Yonsei University, South Korea*

*See next page for additional authors*

**Click here to let us know how access to this document benefits you.**

Follow this and additional works at: [https://uknowledge.uky.edu/pmeh_facpub](https://uknowledge.uky.edu/pmeh_facpub)

Part of the [Environmental Public Health Commons](https://uknowledge.uky.edu/environmentalpublichealthcommons), [Pulmonology Commons](https://uknowledge.uky.edu/pulmonologycommons), and the [Respiratory Tract Diseases Commons](https://uknowledge.uky.edu/respiratorytractdiseasescommons)

**Repository Citation**

Lee, Sei Won; Kim, Hyun Kuk; Baek, Seunghee; Jung, Ji-Ye; Kim, Young Sam; Lee, Jae Seung; Lee, Sang-Do; Mannino, David M.; and Oh, Yeon-Mok, "Development of a Spirometry $T$-score in the General Population" (2016). *Preventive Medicine and Environmental Health Faculty Publications*. 40.  
[https://uknowledge.uky.edu/pmeh_facpub/40](https://uknowledge.uky.edu/pmeh_facpub/40)

This Article is brought to you for free and open access by the Preventive Medicine and Environmental Health at UKnowledge. It has been accepted for inclusion in Preventive Medicine and Environmental Health Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.
Development of a Spirometry T-score in the General Population

© 2016 Lee et al.

Digital Object Identifier (DOI)
https://doi.org/10.2147/COPD.S96117
Development of a spirometry $T$-score in the general population

Sei Won Lee¹
Hyun Kuk Kim²
Seunghee Baek³
Ji-Ye Jung⁴
Young Sam Kim⁴
Jae Seung Lee⁴
Sang-Do Lee⁴
David M Mannino⁵
Yeon-Mok Oh¹

¹Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ²Department of Pulmonary and Critical Care Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, ³Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, ⁴Division of Pulmonary, Department of Internal Medicine, Institute of Chest Disease, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; ⁵Department of Preventive Medicine and Environmental Health, University of Kentucky College of Public Health, Lexington, KY, USA

Background and objective: Spirometry values may be expressed as $T$-scores in standard deviation units relative to a reference in a young, normal population as an analogy to the $T$-score for bone mineral density. This study was performed to develop the spirometry $T$-score.

Methods: $T$-scores were calculated from lambda-mu-sigma-derived $Z$-scores using a young, normal age reference. Three outcomes of all-cause death, respiratory death, and COPD death were evaluated in 9,101 US subjects followed for 10 years; an outcome of COPD-related health care utilization (COPD utilization) was evaluated in 1,894 Korean subjects followed for 4 years.

Results: The probability of all-cause death appeared to remain nearly zero until $\sim$1 of forced expiratory volume in 1 second ($FEV_1$) $T$-score but increased steeply where $FEV_1$ $T$-score reached below $\sim$2.5. Survival curves for all-cause death, respiratory death, COPD death, and COPD utilization differed significantly among the groups when stratified by $FEV_1$, $T$-score ($P<$0.001). The adjusted hazard ratios of the $FEV_1$ $T$-score for the four outcomes were 0.54 (95% confidence interval, 0.48–0.60), 0.43 (95% CI: 0.37–0.50), 0.30 (95% CI: 0.24–0.37), and 0.69 (95% CI: 0.59–0.81), respectively, adjusting for covariates ($P<$0.001).

Conclusion: The spirometry $T$-score could predict all-cause death, respiratory death, COPD death, and COPD utilization.

Keywords: spirometry, $T$-score, COPD

Introduction

Spirometry can indicate various lung diseases and help determine their treatment and prognosis.¹ The role of spirometry values, including forced expiratory volume in 1 second ($FEV_1$) and the ratio of $FEV_1$ to forced vital capacity ($FEV_1$/FVC), is well established in the diagnosis, the classification of disease severity, and the prediction of mortality for patients with COPD.²

However, the method used to define the cut-off value of airflow limitation for the diagnosis of COPD has been debated by two groups. One group suggested that the cut-off value of airflow limitation be defined by a fixed ratio ($FEV_1$/FVC <0.70 or/and $FEV_1$ <80% of predicted value),³ while the other group suggested that the cut-off value of airflow limitation by the lower limit of normal ($FEV_1$/FVC or/and $FEV_1$ < less than the bottom 5% percentile of normal reference value) which has the same meaning as “the $Z$-score of $FEV_1$/FVC or/and $FEV_1$ $\sim$1.64”⁴. In addition to both of these suggestions, there is a third method used to define the cut-off value of airflow limitation, a spirometry $T$-score. Similar to defining the $T$-score of bone mineral density, spirometry $T$-score can be defined by the spirometry values corrected with the young age where the lung function is at peak. Older subjects are more vulnerable to, and have poorer outcomes due to respiratory diseases even though they may have the same spirometry values that are expressed in spirometry $Z$-score.⁵,⁶ In the present study, we hypothesized that

Correspondence: Yeon-Mok Oh
Department of Pulmonary and Critical Care Medicine, Clinical Research Center for Chronic Obstructive Airway Diseases, Asan Medical Center, University of Ulsan College of Medicine, 86 Asanjaeongwon-gil, Songpa-gu, Seoul 138-736, Korea
Tel +82 2 3010 3136
Fax +82 2 3010 6968
Email ymoh55@amc.seoul.kr
spirometry T-score may better predict the four outcomes of all-cause death, respiratory death, COPD death, and COPD-related health care utilization (COPD utilization).

In this study, we developed the spirometry T-score. In addition, we compared the three methods of the fixed ratio, the spirometry Z-score, and T-score to answer the question as to which method has the best prediction performance for the four outcomes.

Methods
Overview
We performed this study using representative samples of the two general populations, the US and Korean. In relation to the spirometry values, the three outcomes of all-cause death, respiratory death, and COPD death were evaluated in 9,101 subjects followed for 10 years in the Third National Health and Nutrition Examination Survey (US NHANES III). The fourth outcome of COPD utilization was evaluated in 1,894 subjects followed for 4 years in the Second Korean National Health and Nutritional Examination Survey (Korean NHANES II).

Calculation of spirometry Z-scores and T-scores
We developed the spirometry T-score by analogy to the bone mineral density T-score, which is expressed in standard deviation units relative to a reference in a young, normal population. However, in addition to age, spirometry values are also dependent on height. Therefore, taking into consideration age and height for the development of a spirometry T-score, we used the lambda-mu-sigma (LMS) method, where spirometry values of median (mu), coefficient of variation (sigma), and skewness (lambda) were modeled.

For the 9,101 US subjects, we calculated spirometry Z-scores and T-scores using look-up tables using a Microsoft Excel (Microsoft Corporation, Redmond, WA, USA) add-in module, which has been developed by Stanojevic et al. The young, normal reference for FEV₁ and the FEV₁/FVC ratio in the US population was the value at 23 years of age in males and 22 years of age in females, which are the ages when the median FEV₁ is the highest.

As for the 1,894 Korean subjects, we calculated spirometry Z-scores and T-scores using Korean reference equations developed with the LMS method (Table S1). The age of the young, normal reference for FEV₁ and the FEV₁/FVC ratio, was 19 years in males and 32 years in females for Koreans.

US NHANES III data
We used anonymous, publically available data of 9,101 subjects from the US NHANES III, which is a large, representative, stratified, random survey of the US population from 8 to 80 years of age. For this study, we used only the data of non-Hispanic white participants 17–80 years of age, who completed at least three acceptable spirometry maneuvers and also whose mortality status and height were available (Figure S1). The spirometry methods used in the US NHANES III have been described previously by Hankinson et al and in Centers for Disease Control and Prevention.

All-cause death, respiratory death, and COPD death after 10 years of follow-up
The US NHANES III recorded all-cause deaths, which were ascertained from a public-use-linked mortality file that contains information based on the National Death Index. Deaths from a respiratory cause were defined by the International Classification of Diseases (ICD) J10–J98 codes; deaths from COPD were defined the ICD codes of J40–J47 (but not including the asthma codes J45 or J46).

Survival curves and hazard ratios of spirometry T-scores
The Kaplan–Meier survival curves for the groups stratified by their spirometry T-scores were calculated with the log-rank test. The stratification of groups for the Kaplan–Meier curves was determined arbitrarily, but the first level of cut-off was determined with FEV₁ T-score of −2.5, below which the probability of all-cause death appeared to increase steeply (Figure 1). Hazard ratios of the spirometry T-score for death was calculated by Cox proportional hazard analysis with adjustment for age, sex, smoking history, and co-morbidity, including cancer, heart attack, heart failure, and diabetes.

COPD utilization during 4 years of follow-up
We linked the data of 1,894 subjects that were 40 years of age or older of the Korean NHANES II with the Korean National Health Insurance claims (Figure S2). In this study, we considered that health care utilization related to COPD occurred if a participant in KHANES II in 2001 used health care services including any procedures, tests, or treatments with a primary diagnosis of COPD between 2002 and 2005 based on data from Korean National Health Insurance claims.

Statistical analyses
Statistical analyses were performed using SPSS software, version 18.0 (SPSS Inc., Chicago, IL, USA) and SAS 9.2 (SAS Institute Inc., Cary, NC, USA). In addition, pROC in the R 2.15.2 software package for statistical computing
Probability of all-cause death after 10 years

Figure 1: Probability of all-cause death (A–F), respiratory death (G), COPD death (H), and COPD-related health care utilization (I).

Notes: Probability of all-cause death after 10 years was shown according to FEV₁ expressed in T-score, Z-score, and % of predicted value (A–C) and according to the ratio of FEV₁/FVC expressed in T-score, Z-score, and the ratio itself (D–F) in the 9,101 US subjects. Probability of respiratory death and COPD death after 10 years was shown according to FEV₁ T-score (G and H) in the 9,101 US subjects. Probability of COPD-related health care utilization during 4 years of follow-up was shown according to FEV₁ T-score (I) in the 1,894 Korean subjects.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; F-U, follow-up.
Table 1 Baseline characteristics of subjects included in this study

<table>
<thead>
<tr>
<th></th>
<th>US subjects</th>
<th>Korean subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects (%)</td>
<td>9,101 (100%)</td>
<td>1,894 (100%)</td>
</tr>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17–39</td>
<td>4,092 (45.0%)</td>
<td>N/a</td>
</tr>
<tr>
<td>40–64</td>
<td>3,247 (35.7%)</td>
<td>1,618 (85.4%)</td>
</tr>
<tr>
<td>≥ 65</td>
<td>1,762 (19.4%)</td>
<td>276 (14.6%)</td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>4,460 (49.0%)</td>
<td>924 (48.8%)</td>
</tr>
<tr>
<td>Female</td>
<td>4,641 (51.0%)</td>
<td>970 (51.2%)</td>
</tr>
<tr>
<td>Smoking status</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smoker</td>
<td>4,395 (48.3%)</td>
<td>1,112a (59.9%)</td>
</tr>
<tr>
<td>Current or ex-smoker</td>
<td>4,706 (51.7%)</td>
<td>745 (40.1%)</td>
</tr>
<tr>
<td>Comorbidity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer</td>
<td>676 (7.4%)</td>
<td>N/a</td>
</tr>
<tr>
<td>Heart attack</td>
<td>334 (3.7%)</td>
<td>N/a</td>
</tr>
<tr>
<td>Heart failure</td>
<td>223 (2.5%)</td>
<td>N/a</td>
</tr>
<tr>
<td>Diabetes</td>
<td>605 (6.7%)</td>
<td>N/a</td>
</tr>
<tr>
<td>Hypertension</td>
<td>2,122 (23.5%)</td>
<td>N/a</td>
</tr>
</tbody>
</table>

Notes: The US subjects and Korean subjects were the participants of the Third National Health and Nutrition Examination Survey (US NHANES III) and the Second Korean National Health and Nutrition Examination Survey (Korean NHANES II), respectively. a The smoking history of 37 subjects was missing.

Abbreviations: FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; N/a, not applicable.

The prediction performance of FEV1/FVC ratio itself was comparable to that of FEV1/FVC T-score for the prediction of respiratory death and COPD death (P<0.001 for all comparisons; Figure 2E–G), and was even higher than that of FEV1/FVC T-score for the prediction of all-cause death (P<0.001 for both comparisons; Figure 2E). The prediction performance of the FEV1/FVC ratio was higher than that of FEV1/FVC Z-score for the prediction of all-cause death, respiratory death, COPD death, and COPD utilization (P<0.001 for all comparisons; Figure 2E–G).

Cut-off values of spirometry T-scores for the prediction of all-cause death

The cut-off values of the FEV1 T-score that reached the maximum Youden index (sensitivity + specificity −1) for the prediction of all-cause death were −2.5 in males and −2.4 in females. The corresponding FEV1/FVC T-scores were −1.1 in males and −1.6 in females. For the prediction of 10-year all-cause death, an FEV1 T-score of −2.5 had a sensitivity

<table>
<thead>
<tr>
<th>Spirometry values</th>
<th>FEV1 T-score</th>
<th>FEV1 Z-score</th>
<th>FEV1 % of predicted value</th>
<th>FEV1/FVC T-score</th>
<th>FEV1/FVC Z-score</th>
<th>FEV1/FVC ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td>US subjects</td>
<td>−1.52±1.76</td>
<td>−0.35±1.24</td>
<td>89.0±16.8</td>
<td>−0.89±1.03</td>
<td>−0.21±0.97</td>
<td>0.78±0.09</td>
</tr>
<tr>
<td>Korean subjects</td>
<td>−0.83±1.26</td>
<td>0.21±1.10</td>
<td>95.0±14.6</td>
<td>−0.67±0.79</td>
<td>−0.26±0.86</td>
<td>0.78±0.08</td>
</tr>
</tbody>
</table>

Notes: For the prediction of all-cause death, respiratory death, and COPD death, the prediction performance of the FEV1 T-score was higher than that of the FEV1 Z-score or the FEV1 percent of predicted value (P<0.001 for all comparisons; Figure 2A–C). As for the T-score of FEV1/FVC, the prediction performance was lower than FEV1 T-score (P<0.05 for all comparisons; Figure 2A–C and E–G).
Figure 2. Receiver operating characteristic (ROC) curves for the prediction of all-cause death (A and E), respiratory death (B and F), COPD death (C and G), and COPD-related health care utilization (D and H).

Notes: ROC curves for the prediction of death were shown according to FEV₁ expressed in T-score, Z-score, and % of predicted value (A–C) and according to the ratio of FEV₁/FVC expressed in T-score, Z-score, and the ratio itself (E–G) in the 9,101 US subjects. ROC curves for the prediction of COPD-related health care utilization were shown according to FEV₁ expressed in T-score, Z-score, and % of predicted value (D) and according to the ratio of FEV₁/FVC expressed in T-score, Z-score, and the ratio (H) in the 1,894 Korean subjects.

Abbreviations: AUC, area under curve; CI, confidence interval; FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity; F-U, follow-up.
of 0.78 and a specificity of 0.78, which were higher than the indices calculated using the other criteria of abnormal spirometry (Table 2).

For the prediction of COPD death, the FEV₁/FVC ratio with the cut-off value of 0.70 appeared to be comparable to FEV₁ T-score with the cut-off value of –2.5 (Table 2).

Survival curves and hazard ratios of the FEV₁ T-score
Survival curves for all-cause death, respiratory death, and COPD death differed significantly among the groups when stratified into four groups (<–4.5, –4.5 to –3.6, –3.5 to –2.6, and ≥–2.5) by FEV₁ T-score (P < 0.001 for all log-rank tests; Figure 3A–C).

The adjusted hazard ratios of the FEV₁ T-score for all-cause death, respiratory death, and COPD death were 0.54 (95% CI: 0.48–0.60), 0.43 (95% CI: 0.37–0.50), and 0.30 (95% CI: 0.24–0.37), respectively, adjusting for age, sex, smoking history, and co-morbidity in the US subjects (P < 0.0001 for all Cox proportional hazard analyses).

Results from the analyses of the Korean NHANES II
Subject characteristics
Among 1,894 subjects from the Korean NHANES II data, 51% were female. The mean age was 53 years, and 40% had a smoking history (Table 1). COPD utilization was observed for 156 (8.2%) subjects during 4 years of follow-up.

Spirometry T-score for the prediction of COPD utilization
The probability of COPD utilization during 4 years of follow-up increased steeply as FEV₁ T-score decreased to negative values (Figure 11).

For the prediction of COPD utilization, the prediction performance of the FEV₁ T-score was higher than that of the FEV₁ Z-score or the FEV₁ percent of predicted value (P < 0.05 for both comparisons; Figure 2D). As for the ratio of FEV₁/FVC, the prediction performance was higher than that of FEV₁/FVC T-score or Z-score for the prediction of COPD utilization (P < 0.05 for both comparisons; Figure 2H).

As for the prediction of COPD utilization, the cut-off value of FEV₁ T-score was –1.5 and this reached the maximum of Youden index (Table S2).

Survival curves and hazard ratios of the FEV₁ T-score
Survival curves for COPD utilization differed significantly among the groups when stratified by FEV₁ T-score (P < 0.001...
for log-rank test; Figure 3D). The adjusted hazard ratio of the FEV₁ T-score for COPD utilization was 0.69 (95% CI: 0.59–0.81) adjusting for age, sex, amount smoked, monthly income, presence of pulmonary symptoms, and physician-diagnosed COPD in the Korean subjects (P<0.001; Cox proportional hazard analysis).

**Discussion**

In this study, we developed a spirometry T-score that could predict all-cause death, respiratory death, and COPD death in the US population and COPD utilization in the Korean population. This study suggests that spirometry values might also be corrected in the same way as that of the diagnosis of osteoporosis for which a young, normal reference is used to determine T-scores of bone mineral density. The rationale for using T-score might be that the age-related vulnerability should be taken into account;³,⁵,⁶ the rationale for Z-scores is that the age-related variability should be taken into account.

We found that the probability of all-cause death appeared to increase steeply when the FEV₁ T-score decreased below approximately −2.5 (Figure 1A). We also found that the optimal cut-off values of the FEV₁ T-score for the prediction of all-cause death were −2.5 in males and −2.4 in females, where the Youden index reached the maximum value. However, which cut-off value of spirometry should be chosen might be dependent on the outcome. As for the outcome of COPD utilization, the cut-off value of −1.5 in FEV₁ T-score was the value where Youden index was the maximum (Table S2).

We also found that the prediction performance of FEV₁/FVC ratio itself was comparable to, or even better than that of FEV₁/FVC T-score, for the prediction of all-cause death, respiratory death, COPD death, and COPD utilization (Figure 2E–H). In addition, the criteria of abnormal spirometry by “FEV₁/FVC <0.70” were comparable to that by “FEV₁ T-score <−2.5” for the prediction of COPD death (Table 2).
However, the prediction performance of FEV\textsubscript{1}/FVC Z-score did not appear to be as good as that of FEV\textsubscript{1}/FVC ratio itself or T-score. The prediction performance for COPD death had a sensitivity of 0.63 and a specificity of 0.93, with a Youden index of 0.56 given that the criterion of abnormal spirometry was an FEV\textsubscript{1}/FVC ratio less than the lower limit of normal, bottom 5% percentile (which has the same meaning as an FEV\textsubscript{1}/FVC Z-score less than −1.64) (Table 2). If the criterion FEV\textsubscript{1}/FVC <0.70 was chosen, then the sensitivity would be 0.79 and specificity 0.85, with a Youden index of 0.64. These results might suggest that the definition of airflow limitation using the FEV\textsubscript{1}/FVC criterion of less than 0.70, suggested by the COPD clinical practice guidelines.

The T-score of bone mineral density is known to reflect future fracture risk. A recent meta-analysis found that fracture risk increases by 1.5-fold to 2.6-fold for every unit decrease in standard deviation of mean bone mineral density. In our study, one standard deviation decrease in FEV\textsubscript{1} T-score increased the risk of all-cause death by 1.9 times (the reciprocal of 0.54), respiratory death by 2.3 times (1/0.43), COPD death by 3.3 times (1/0.30), and COPD-related health care utilization by 1.4 times (1/0.69). Therefore, FEV\textsubscript{1} T-scores might be comparable to T-scores of bone mineral density.

There are some limitations to discuss. First, determining cause of death is not easy or clear, so ICD disease coding might not be as accurate as assumed in this study. However, the large sample size of this study would probably overcome a coding issue. In addition, ICD disease coding has already been validated in previous studies in both US and Korean subjects. Second, to apply these study results to COPD patients, post-bronchodilator spirometry may be needed, because the clinical practice guidelines of COPD management suggest post-bronchodilator spirometry for the diagnosis and classification of COPD. Unfortunately, post-bronchodilator spirometry data are not available for the general population in the US or in Korea. The importance of post-bronchodilator spirometry may be challenged, because the clinical significance of bronchodilator responsiveness is not universally accepted. Third, this study included only white US and Korean participants and therefore, general application to other ethnicities can be limited. For subjects of other ethnicities, a global lung function equation developed by Quanjer et al may be of assistance. Finally, although Youden index is used to determine which methods are superior to others, it is not always informative. The usefulness of Youden index, also the sensitivity and specificity, are mainly determined on the setting or the goal. For example, the FEV/FVC ratio below the LLN would be better than the fixed FEV/FVC ratio in a situation where a physician would be in the clinical context of selecting patients who are not at risk of COPD.

Compared with the conventional diagnostic criteria of COPD, FEV\textsubscript{1} T-score appears to be superior in prediction performance of important outcomes. Therefore, with the superior prediction performance of spirometry T-score, should we use it in clinical practice? Without a consensus of experts or academic societies, we should be prudent to use it in clinical practice, because a vast majority of evidences have been built with the diagnostic criteria of FEV\textsubscript{1}/FVC with a cut-off of 0.70 in research of COPD. Because this study shows that the criteria FEV\textsubscript{1}/FVC of less than 0.70 works acceptably and because spirometry T-score seems to be too complicated to develop, we suggest that the conventional diagnostic criteria of FEV\textsubscript{1}/FVC, with a cut off of 0.70, be acceptable for the diagnosis of COPD in clinical practice.

Conclusion

Spirometry T-score with the age of young, normal reference could predict all-cause death, respiratory death, COPD death, and COPD utilization.

Acknowledgments

This study was supported by a grant of the Korea Healthcare Technology R&D Project, Ministry for Health and Welfare, Republic of Korea (A102065 and H110C2020) and the Obstructive Lung Disease Research Foundation (www.oldrf.org). This study was also supported by grants from the Asan Institute for Life Sciences (14-306).

Author contributions

Sei Won Lee: study design, the US NHANES III data analysis, choosing results, discussing the significance of results, and writing a draft of the manuscript.

Hyun Kuk Kim: study design, the Korean NHANES II data analysis, choosing results, discussing the significance of results, and writing a draft of the manuscript.

Seunghee Baek: study design, the US NHANES III and the Korean NHANES II data analysis, statistical support, choosing results, discussing the significance of results, and writing a draft of the manuscript.

Ji-Ye Jung: study design, linking the Korean NHANES II data to the data of the Korean National Health Insurance claims, discussing the significance of results, and writing a draft of the manuscript.

Young Sam Kim: study design, linking the Korean NHANES II data to the data of the Korean National Health
Insurance claims, discussing the significance of results, and writing a draft of the manuscript.

Jae Seung Lee: study design, data analysis, discussing the significance of results, and writing a draft of the manuscript.

Sang-Do Lee: study design, data analysis, discussing the significance of results, and writing a draft of the manuscript.

David M Mannino: study design, data analysis, discussing the significance of results, and writing a draft of the manuscript.

Yeon-Mok Oh: study design, the US NHANES III and the Korean NHANES II data analysis, choosing results, discussing the significance of results, and writing a draft of the manuscript.

Disclosure
The authors report no conflicts of interest in this work.

References
Supplementary materials

Figure S1 Flow of subjects’ selection from the US NHANES III.
Abbreviation: NHANES III, Third National Health and Nutrition Examination Survey.

Figure S2 Flow of subjects’ selection from the Korean NHANES II.
Abbreviation: NHANES II, Second National Health and Nutritional Examination Survey.

Table S1 Selection of “healthy” subjects for the development of spirometry reference values for Koreans

<table>
<thead>
<tr>
<th>Reasons of exclusion</th>
<th>Number of subjects excluded</th>
<th>Number of subjects who remained</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>4,927*</td>
<td></td>
</tr>
<tr>
<td>History of smoking ≥ 5 packs over whole life</td>
<td>2,038</td>
<td>2,889</td>
</tr>
<tr>
<td>Physician diagnosis of respiratory diseases</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asthma</td>
<td>111</td>
<td>2,778</td>
</tr>
<tr>
<td>COPD</td>
<td>10</td>
<td>2,768</td>
</tr>
<tr>
<td>Lung cancer</td>
<td>0</td>
<td>2,768</td>
</tr>
<tr>
<td>Pulmonary tuberculosis</td>
<td>118</td>
<td>2,650</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>14</td>
<td>2,636</td>
</tr>
<tr>
<td>Respiratory symptoms or limitation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Wheezing during past year</td>
<td>132</td>
<td>2,504</td>
</tr>
<tr>
<td>Wheezing when exercise during past year</td>
<td>68</td>
<td>2,436</td>
</tr>
<tr>
<td>Phlegm more than 3 months during past year</td>
<td>3</td>
<td>2,433</td>
</tr>
<tr>
<td>Cough more than 3 months during past year</td>
<td>0</td>
<td>2,433</td>
</tr>
<tr>
<td>Activity limitation d/t respiratory problem</td>
<td>6</td>
<td>2,427</td>
</tr>
<tr>
<td>Occupational exposure to</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noxious chemicals</td>
<td>72</td>
<td>2,355</td>
</tr>
<tr>
<td>Environmental pollutants</td>
<td>95</td>
<td>2,260</td>
</tr>
<tr>
<td>Missing values</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Height and weight</td>
<td>7</td>
<td>2,253</td>
</tr>
<tr>
<td>FEV₁</td>
<td>1</td>
<td>2,252*</td>
</tr>
</tbody>
</table>

Notes: *Total number of participants for spirometry. †Final number of subjects for the development of spirometric reference equations.
Abbreviations: FEV₁, forced expiratory volume in 1 second; d/t, due to.
Table S2 Various criteria of abnormal spirometry for the prediction of COPD-related health care utilization (COPD utilization)

<table>
<thead>
<tr>
<th>Criteria of abnormal spirometry</th>
<th>COPD-related health care utilization in the Korean subjects</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sensitivity</td>
</tr>
<tr>
<td>FEV₁ T-score &lt;-1.5*</td>
<td>0.50</td>
</tr>
<tr>
<td>FEV₁ Z-score &lt;-1.0*</td>
<td>0.31</td>
</tr>
<tr>
<td>FEV₁ % of predicted value &lt;79</td>
<td>0.31</td>
</tr>
<tr>
<td>FEV₁/FVC T-score &lt;-1.8*</td>
<td>0.24</td>
</tr>
<tr>
<td>FEV₁/FVC Z-score &lt;-1.4*</td>
<td>0.21</td>
</tr>
<tr>
<td>FEV₁/FVC &lt;0.71*</td>
<td>0.37</td>
</tr>
</tbody>
</table>

Notes: The sensitivity and specificity for the prediction of COPD utilization during 4 years of follow-up in the Korean subjects. *The cut-off values were chosen where their Youden indices were the maximum. *Defined as sensitivity + specificity -1.

Abbreviations: FEV₁, forced expiratory volume in 1 second; FVC, forced vital capacity.